SEARCH

SEARCH BY CITATION

References

  • 1
    Mocroft A, Ledergerber B, Katlama C et al. Decline in the AIDS and death rates in the EuroSIDA Study: an observational study. Lancet 2003; 362: 2229.
  • 2
    Palella FJ Jr., Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853860.
  • 3
    Hammer SM, Saag MS, Schechter M et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society–USA Panel. Top HIV Med 2006; 14: 827843.
  • 4
    Josephson F, Albert J, Flamholc L et al. Antiretroviral treatment of HIV infection: Swedish recommendations 2007. Scand J Infect Dis 2007; 39: 486507.
  • 5
    WHO/UNICEF. Towards universal access. Scaling up priority HIV/AIDS interventions in the health sector. Progress Report. June, 2008. Available at http://www.unicef.org/aids/files/towards_universal_access_report_2008.pdf (last accessed 27 July 2009).
  • 6
    UNGASS. 2008 UNGASS Country Progress Report. Available at http://www.unaids.org/en/CountryResponses/Countries/honduras.asp 2008.
  • 7
    Reporte Nacional de VIH/SIDA. Tegucigalpa, Honduras, Programa Nacional de ITS/VIH/SIDA, 2007: 12.
  • 8
    Hirsch MS, Brun-Vezinet F, Clotet B et al. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis 2003; 37: 113128.
  • 9
    Johnson VA, Brun-Vezinet F, Clotet B et al. Update of the drug resistance mutations in HIV-1: 2007. Top HIV Med 2007; 15: 119125.
  • 10
    Pillay D, Green H, Matthias R et al. Estimating HIV-1 drug resistance in antiretroviral-treated individuals in the United Kingdom. J Infect Dis 2005; 192: 967973.
  • 11
    Richman DD, Morton SC, Wrin T et al. The prevalence of antiretroviral drug resistance in the United States. AIDS 2004; 18: 13931401.
  • 12
    Costagliola D, Descamps D, Assoumou L et al. Prevalence of HIV-1 drug resistance in treated patients: a French nationwide study. J Acquir Immune Defic Syndr 2007; 46: 1218.
  • 13
    Knobel H, Alonso J, Casado JL et al. Validation of a simplified medication adherence questionnaire in a large cohort of HIV-infected patients: the GEEMA Study. AIDS 2002; 16: 605613.
  • 14
    Lindstrom A, Albert J. A simple and sensitive ‘in-house’ method for determining genotypic drug resistance in HIV-1. J Virol Methods 2003; 107: 4551.
  • 15
    Tamura K, Dudley J, Nei M, Kumar S. MEGA4: molecular evolutionary genetics analysis (MEGA) software version 4.0. Mol Biol Evol 2007; 24: 15961599.
  • 16
    Centers for Disease Control (CDC). 1993 revised classification system for HIV infection and expanded survillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992; 41(RR-17): 119.
  • 17
    Reynolds S. Evaluation of the WHO Immunologic Criteria for ART Failure among Adults in Rakai, Uganda. 16th Conference on Retroviruses and Opportunistic Infections. Montreal, Canada, February 2009 [Abstract 144].
  • 18
    Mee P, Fielding KL, Charalambous S, Churchyard GJ, Grant AD. Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa. AIDS 2008; 22: 19711977.
  • 19
    Moore DM, Awor A, Downing R et al. CD4 T-cell count monitoring does not accurately identify HIV-infected adults with virologic failure receiving antiretroviral therapy. J Acquir Immune Defic Syndr 2008; 49: 477484.
  • 20
    Tisdale M, Kemp SD, Parry NR, Larder BA. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci USA 1993; 90: 56535656.
  • 21
    Descamps D, Flandre P, Calvez V et al. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilege (Agence Nationale de Recherches sur le SIDA 072) Study Team. JAMA 2000; 283: 205211.
  • 22
    Havlir DV, Hellmann NS, Petropoulos CJ et al. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. JAMA 2000; 283: 229234.
  • 23
    Maguire M, Gartland M, Moore S et al. Absence of zidovudine resistance in antiretroviral-naïve patients following zidovudine/lamivudine/protease inhibitor combination therapy: virological evaluation of the AVANTI 2 and AVANTI 3 Studies. AIDS 2000; 14: 11951201.
  • 24
    Casado JL, Hertogs K, Ruiz L et al. Non-nucleoside reverse transcriptase inhibitor resistance among patients failing a nevirapine plus protease inhibitor-containing regimen. AIDS 2000; 14: F1F7.
  • 25
    Joly V, Moroni M, Concia E et al. Delavirdine in combination with zidovudine in treatment of human immunodeficiency virus type 1-infected patients: evaluation of efficacy and emergence of viral resistance in a randomized, comparative phase III trial. The M/3331/0013B Study Group. Antimicrob Agents Chemother 2000; 44: 31553157.
  • 26
    Chew CB, Potter SJ, Wang B et al. Assessment of drug resistance mutations in plasma and peripheral blood mononuclear cells at different plasma viral loads in patients receiving HAART. J Clin Virol 2005; 33: 206216.
  • 27
    Sarmati L, Nicastri E, Uccella I et al. Drug-associated resistance mutations in plasma and peripheral blood mononuclear cells of human immunodeficiency virus type 1-infected patients for whom highly active antiretroviral therapy is failing. J Clin Microbiol 2003; 41: 17601762.
  • 28
    Karlsson AC, Chapman JM, Heiken BD et al. Antiretroviral drug therapy alters the profile of human immunodeficiency virus type 1-specific T-cell responses and shifts the immunodominant cytotoxic T-lymphocyte response from Gag to Pol. J Virol 2007; 81: 1154311548.